SEARCH

SEARCH BY CITATION

References

  • AURIOLA, S., FRITH, J.C., ROGERS, M.J., KOIVUNIEMI, A. & MÖNKKÖNEN, J. (1997). Identification of adenine nucleotide-containing metabolites of bisphosphonate drugs using ion-pair liquid chromatography-electrospray mass spectrometry. J. Chromatogr. B, 704, 187195.
  • BENFORD, H.L., FRITH, J.C., AURIOLA, S., MÖNKKÖNEN, J. & ROGERS, M.J. (1999). Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. Mol. Pharmacol., 56, 131140.
  • BOYDE, A., ALI, N.N. & JONES, S.J. (1984). Resorption of dentine by isolated osteoclasts in vitro. Br. Dent. J., 156, 216220.
  • CHAMBERS, T.J., THOMSON, B.M. & FULLER, K. (1984). Effect of substrate composition on bone resorption by rabbit osteoclasts. J. Cell Sci., 70, 6171.
  • CHAVEZ, E., ZAZUETA, C. & GARCIA, N. (1999). Carboxyatractyloside increases the effect of oleate on mitochondrial permeability transition. FEBS Lett., 445, 189191.
  • COLEMAN, R.E. (2001). Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat. Rev., 27, 165176.
  • DELMAS, P.D. (2002). Treatment of postmenopausal osteoporosis. Lancet, 359, 20182026.
  • DUNFORD, J.E., THOMPSON, K., COXON, F.P., LUCKMAN, S.P., HAHN, F.M., POULTER, C.D., EBETINO, F.H. & ROGERS, M.J. (2001). Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J. Pharmacol. Exp. Ther., 296, 235242.
  • EGGERER, H. & LYNEN, F. (1960). Biosynthesis of terpenes. VIII. Synthesis of 3-methyl-buten-3-yl 1-pyrophosphate. Ann. Chem., 630, 5870.
  • FRITH, J.C., MÖNKKÖNEN, J., AURIOLA, S., MÖNKKÖNEN, H. & ROGERS, M.J. (2001). The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis. Arthritis Rheum., 44, 22012210.
  • GOBER, H.J., KISTOWSKA, M., ANGMAN, L., JENO, P., MORI, L. & DE LIBERO, G. (2003). Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J. Exp. Med., 197, 163168.
  • GREEN, J.R. (2003). Antitumor effects of bisphosphonates. Cancer, 97, 840847.
  • HALESTRAP, A.P. (2004). Mitochondrial permeability: dual role for the ADP/ATP translocator Nature, 430, 984.
  • HUGHES, D.E., WRIGHT, K.R., UY, H.L., SASAKI, A., YONEDA, T., ROODMAN, G.D., MUNDY, G.R. & BOYCE, B.F. (1995). Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J. Bone Miner. Res., 10, 14781487.
  • KOKOSZKA, J.E., WAYMIRE, K.G., LEVY, S.E., SLIGH, J.E., CAI, J., JONES, D.P., MACGREGOR, G.R. & WALLACE, D.C. (2004). The ADP/ATP translocator is not essential for the mitochondrial permeability transition pore. Nature, 427, 461465.
  • KROEMER, G. & REED, J.C. (2000). Mitochondrial control of cell death. Nat. Med., 6, 513519.
  • LEHENKARI, P.P., KELLINSALMI, M., NÄPANKANGAS, J.P., YLITALO, K.V., MÖNKKÖNEN, J., ROGERS, M.J., AZHAYEV, A., VÄÄNÄNEN, H.K. & HASSINEN, I.E. (2002). Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol. Pharmacol., 61, 12551262.
  • MAYER, B. & OBERBAUER, R. (2003). Mitochondrial regulation of apoptosis. News Physiol. Sci., 18, 8994.
  • MÖNKKÖNEN, H., MOILANEN, P., MÖNKKÖNEN, J., FRITH, J.C., ROGERS, M.J. & AURIOLA, S. (2000). Analysis of an adenine nucleotide-containing metabolite of clodronate using ion pair high-performance liquid chromatography electrospray ionization mass spectrometry. J. Chromatogr. B, 738, 395403.
  • MÖNKKÖNEN, H., ROGERS, M.J., MAKKONEN, N., NIVA, S., AURIOLA, A. & MÖNKKÖNEN, J. (2001). The cellular uptake and metabolism of clodronate in RAW 264 macrophages. Pharm. Res., 18, 15501555.
  • MÖNKKÖNEN, J., TASKINEN, M., AURIOLA, S.O. & URTTI, A. (1994a). Growth inhibition of macrophage-like and other cell types by liposome-encapsulated, calcium-bound, and free bisphosphonates in vitro. J. Drug Target., 2, 299308.
  • MÖNKKÖNEN, J., VALJAKKA, R., HAKASALO, M. & URTTI, A. (1994b). The effects of liposome surface charge and size on the intracellular delivery of clodronate and gallium in vitro. Int. J. Pharm., 107, 189197.
  • NEVILLE-WEBBE, H.L., ROSTAMI-HODJEGAN, A., EVANS, C.A., COLEMAN, R.E. & HOLEN, I. (2005). Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells. Int. J. Cancer, 113, 364371.
  • PAULSON, D.J. & SHUG, A.L. (1984). Inhibition of the adenine nucleotide translocator by matrix-localized palmityl-CoA in rat heart mitochondria. Biochim. Biophys. Acta, 766, 7076.
  • ROGERS, M.J. (2003). New insights into the molecular mechanisms of action of bisphosphonates. Curr. Pharm. Des., 9, 26432658.
  • ROGERS, M.J., BROWN, R.J., HODKIN, V., BLACKBURN, G.M., RUSSELL, R.G. & WATTS, D.J. (1996). Bisphosphonates are incorporated into adenine nucleotides by human aminoacyl-tRNA synthetase enzymes. Biochem. Biophys. Res. Commun., 224, 863869.
  • ROUX, C. & DOUGADOS, M. (1999). Treatment of patients with Paget's disease of bone. Drugs, 58, 823830.
  • SALO, J., LEHENKARI, P., MULARI, M., METSIKKÖ, K. & VÄÄNÄNEN, H.K. (1997). Removal of osteoclast bone resorption products by transcytosis. Science, 11, 270273.
  • SATO, M., GRASSER, W., ENDO, N., AKINS, R., SIMMONS, H., THOMPSON, D.D., GOLUB, E. & RODAN, G.A. (1991). Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J. Clin. Invest., 88, 20952105.
  • WATANABE, F., HASHIMOTO, T. & TAGAWA, K. (1985). Energy-independent protection of the oxidative phosphorylation capacity of mitochondria against anoxic damage by ATP and its non-metabolizable analogs. J. Biochem., 97, 12291234.
  • ZAMZAMI, N., MARCHETTI, P., CASTEDO, M., HIRSCH, T., SUSIN, S.A., MASSE, B. & KROEMER, G. (1996). Inhibitors of permeability transition interfere with the disruption of the mitochondrial transmembrane potential during apoptosis. FEBS Lett., 384, 5357.